Chairperson: Claire Skentelbery, Director General EuropaBio
Kostas Papagiannis Country President & Managing Director Novartis Greece
Hardy Rideout Anacalypsis Therapeutics
George Drakakis CEO Purposeful
EU pharma legislation is going to change your business. What you make, where and how you sell it, and whether your business model is even viable.
The European Commission published new legislative proposals in April that will redefine the business model of biotechnology in Europe. In trying to bring medicines to more patients, the legislation proposals reduce data protection, limit exclusivity for orphan medicines and brings heavy pressure to launch in all 27 Member States within two years of EMA approval.
Changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups, those seeking scale up investment, clinical trials and companies going to market, often for the first time.
This session/panel, chaired by EuropaBio, presents the key impacts points for biotechnology innovation within Greece, with contributions from small and large companies and policy makers – bring your voice to the discussion for the future of your own science.